Supplements

Vitamin E

Updated · 48 sources

Vitamin E is a family of eight fat-soluble antioxidants made by plants: four tocopherols and four tocotrienols. Only one of them, alpha-tocopherol, is recognized as meeting human requirements. The adult US RDA is 15 mg/day, and overt deficiency is rare in healthy people.

People take vitamin E hoping to protect the heart, prevent cancer or recover faster from exercise, and most vitamin E-only products provide well above the RDA. Large randomized trials do not support those uses. In 2022 the US Preventive Services Task Force recommended against vitamin E for preventing cardiovascular disease or cancer. High doses have also been linked to hemorrhagic stroke, and in one large trial to prostate cancer. The strongest case for a benefit is narrower: improved liver histology in some people with steatohepatitis.

This page summarizes what the NIH Office of Dietary Supplements, the European Food Safety Authority and clinical trials report. It is for education only and is not medical advice.

Property Detail
Type Essential fat-soluble vitamin; dietary supplement ingredient
Main supplement forms Natural RRR-alpha-tocopherol (d-), synthetic all-rac-alpha-tocopherol (dl-), their acetate and succinate esters; some mixed tocopherol and tocotrienol products
Adult RDA (US) 15 mg/day; 19 mg/day in lactation
Upper limit (adults) US: 1,000 mg/day from supplements. EU: 300 mg/day from all dietary sources
Potency 1 mg alpha-tocopherol = 1 mg natural = 2 mg synthetic
Doses in cited trials 50 mg/day (ATBC); 400 IU/day (HOPE, SELECT); 800 IU/day (PIVENS)
Half-life About 30 h for labeled alpha-tocopherol from food; 2.3–4.4 h for tocotrienols
USPSTF Recommends against use for preventing cardiovascular disease or cancer (D recommendation, 2022)
WADA status Not named on the 2026 Prohibited List

What it is

The eight natural forms share similar ring structures. Tocopherols have a phytyl side chain, and tocotrienols have an unsaturated one (EFSA 2024).

After absorption, the liver takes up all forms. Its alpha-tocopherol transfer protein preferentially puts alpha-tocopherol back into the blood, while the other forms are metabolized and excreted. For this reason US and European bodies base their vitamin E values on alpha-tocopherol alone (NIH ODS; EFSA 2024).

Vitamin E stops the chain reaction of reactive oxygen species formed when fats oxidize. It also has non-antioxidant actions. Alpha-tocopherol inhibits protein kinase C, and vitamin E raises prostacyclin release from blood vessel walls, which widens vessels and inhibits platelet clumping. Platelet inhibition, along with opposition to vitamin K, is the proposed basis of its bleeding risk (NIH ODS).

Natural vs synthetic alpha-tocopherol

Feature Natural Synthetic
Chemical name RRR-alpha-tocopherol all-rac-alpha-tocopherol
Common label d-alpha-tocopherol dl-alpha-tocopherol
Stereoisomers One Eight in equal amounts; blood and tissues maintain only four
Activity per mg Full About half
1 IU equals 0.67 mg alpha-tocopherol 0.45 mg alpha-tocopherol

Those conversions come from the NIH ODS. Labels now list vitamin E in mg, while most older trials report IU, so “400 IU” means about 268 mg of alpha-tocopherol in natural form and 180 mg in synthetic form.

A human study using deuterium labels gave both forms together. Plasma ratios of natural to synthetic settled at about 2:1, higher than the 1.36:1 accepted at the time (Burton et al., Am J Clin Nutr 1998). The study was small: two groups of five adults, 22 surgical patients and two terminally ill patients.

Esters such as alpha-tocopheryl acetate and succinate extend shelf life, and the body hydrolyzes and absorbs them as efficiently as free alpha-tocopherol. People with fat malabsorption sometimes need a water-soluble form, tocopheryl polyethylene glycol-1000 succinate (NIH ODS).

Tocotrienols and other forms

Gamma-tocopherol from soybean, canola and corn oils is the main form in American diets, but it is not what the RDA measures (NIH ODS). Tocotrienols do not count toward the RDA and have been studied far less than alpha-tocopherol. The human trials below measured surrogate markers, not clinical outcomes:

  • Lipids. A meta-analysis of 15 articles found that tocotrienols raised HDL cholesterol (0.146 mmol/L) but did not lower total cholesterol, LDL or triglycerides overall. Heterogeneity was high (Zuo et al., Complement Ther Med 2020).
  • Fatty liver. In a double-blind trial of 100 patients with NAFLD, delta-tocotrienol 300 mg and alpha-tocopherol 268 mg, each twice daily for 48 weeks, improved steatosis measures equally. Delta-tocotrienol lowered body weight and some inflammatory markers more. There was no placebo arm and no liver biopsy endpoint (Pervez et al., Complement Ther Med 2022).

How it behaves in the body

Absorption requires dietary fat, which is why fat-malabsorption disorders can cause deficiency (NIH ODS).

Measure Alpha-tocopherol (labeled, from collard greens; n = 41) Tocotrienols (300 mg mixed dose; n = 8)
Half-life 30 ± 11 h 4.4 h (alpha), 4.3 h (gamma), 2.3 h (delta)
Time to peak 12.6 ± 2.5 h No difference between fed and fasted
Food effect Minimum 24% ± 16% absorbed from a test breakfast Fed vs fasted exposure (AUC) ratio, 90% CI: 2.24–3.40 (alpha), 2.05–4.09 (gamma), 1.59–3.81 (delta)
Source Traber et al., Am J Clin Nutr 2015 Yap et al., J Pharm Pharmacol 2001

In the Traber study, alpha-tocopherol stayed in circulation longer in people with higher blood lipids, and neither half-life nor absorption varied by age.

Measuring status

Status is not routinely tested. Mean serum alpha-tocopherol in the US is about 30 μmol/L, and deficiency is usually defined as under 12 μmol/L. Blood levels track blood lipids and correlate poorly with intake, so they can identify inadequacy but not confirm adequacy (NIH ODS).

Intake recommendations and upper limits

US values from the Food and Nutrition Board, as listed by the NIH ODS:

Group RDA (mg/day) UL (mg/day, supplemental)
Infants 0–6 months 4 (AI) Not established
Infants 7–12 months 5 (AI) Not established
Children 1–3 years 6 200
Children 4–8 years 7 300
Ages 9–13 years 11 600
Ages 14–18 years 15 800
Adults 19 years and older 15 1,000
Pregnancy (adult) 15 1,000
Lactation (adult) 19 1,000

The RDA covers nearly all (97%–98%) healthy people, and the AI (Adequate Intake) is used when evidence is too thin to set an RDA. The UL (Tolerable Upper Intake Level) is the highest daily intake unlikely to cause harm. The 1,000 mg adult limit equals 1,500 IU of natural or 1,100 IU of synthetic vitamin E. The limit covers all forms of supplemental alpha-tocopherol, so the synthetic IU figure does not follow the activity-based conversion in the table above.

European values are lower:

  • Adequate intake. EFSA set an AI of 13 mg/day for men and 11 mg/day for women, with no increase in pregnancy or lactation (EFSA 2015).
  • Upper limit. In 2024 EFSA kept the adult UL at 300 mg/day from all dietary sources, with impaired clotting as the critical effect. The limit does not apply to people taking anticoagulant or antiplatelet drugs such as aspirin, patients on secondary prevention for cardiovascular disease, or people with vitamin K malabsorption (EFSA 2024).

The gap reflects different starting points. The US limit derives from a lowest adverse effect level of 500 mg/kg/day in rats with an uncertainty factor of 36. The European limit derives from a no-adverse-effect level of 540 mg/day (800 IU) in a human study with an uncertainty factor of 2 (EFSA 2024). The ODS notes that data supporting the US limit are limited and come from small groups followed for weeks or months.

Food sources and supplements

The NIH ODS lists these examples from USDA data:

Food Alpha-tocopherol per serving
Wheat germ oil, 1 tablespoon 20.3 mg
Sunflower seeds, dry roasted, 1 ounce 7.4 mg
Almonds, dry roasted, 1 ounce 6.8 mg
Sunflower oil, 1 tablespoon 5.6 mg
Hazelnuts, dry roasted, 1 ounce 4.3 mg
Peanut butter, 2 tablespoons 2.9 mg
Spinach, boiled, half cup 1.9 mg

In US survey data from August 2021 to August 2023, people aged 2 and older averaged 9.8 mg/day (males) and 8.5 mg/day (females) from food and beverages, below the adult RDA. These figures may be underestimates because cooking fats are often not captured. Most vitamin E-only supplements provide 67 mg (100 IU) or more (NIH ODS).

Overt deficiency is rare and has not been seen in healthy people on low-vitamin E diets. It causes anemia, peripheral neuropathy, ataxia, muscle weakness, retinal damage and impaired immunity. Those at risk include very low birthweight preterm infants and people with fat malabsorption (such as Crohn’s disease or cystic fibrosis). Two rare inherited disorders, abetalipoproteinemia and ataxia with vitamin E deficiency, require large doses under medical care (NIH ODS).

What the research shows

Cardiovascular disease and cancer: the large trials

Early observational studies linked higher vitamin E intake to less heart disease. One study of about 90,000 nurses reported 30%–40% lower incidence with the highest intakes, mainly from supplements (NIH ODS). Randomized trials did not confirm this:

Trial Who Dose and form Follow-up Main results
ATBC, NEJM 1994 29,133 male smokers aged 50–69 50 mg/day synthetic 5–8 years Lung cancer −2% (95% CI −14% to 12%); fewer prostate cancers; no apparent effect on total mortality; more hemorrhagic stroke deaths
HOPE and HOPE-TOO, Lonn et al., JAMA 2005 9,541 patients aged 55 or older with vascular disease or diabetes 400 IU/day natural Median 7.0 years Major cardiovascular events RR 1.04 (95% CI 0.96–1.14); cancer RR 0.94 (0.84–1.06); heart failure RR 1.13 (1.01–1.26)
Women’s Health Study, Lee et al., JAMA 2005 39,876 healthy women aged 45 or older 600 IU natural on alternate days Mean 10.1 years Major cardiovascular events RR 0.93 (0.82–1.05); cardiovascular death RR 0.76 (0.59–0.98); total cancer RR 1.01 (0.94–1.08); total mortality RR 1.04 (0.93–1.16)
Physicians’ Health Study II, Sesso et al., JAMA 2008; Gaziano et al., JAMA 2009 14,641 male physicians aged 50 or older 400 IU synthetic on alternate days Mean 8 years Major cardiovascular events HR 1.01 (0.90–1.13); hemorrhagic stroke HR 1.74 (1.04–2.91); prostate cancer HR 0.97 (0.85–1.09); total cancer HR 1.04 (0.95–1.13)
SELECT, Klein et al., JAMA 2011 35,533 men randomized; 34,887 analyzed 400 IU/day synthetic Planned 7–12 years; supplements stopped early Prostate cancer HR 1.17 (99% CI 1.004–1.36), or 1.6 extra cases per 1,000 person-years

The Women’s Health Study’s lower cardiovascular death was a secondary finding, and the primary composite outcome was not significantly changed. Its authors concluded that the data do not support recommending vitamin E for prevention.

A 2022 evidence review for the USPSTF pooled trials in adults without cardiovascular disease or cancer. Vitamin E was not significantly associated with any main outcome (O’Connor et al., JAMA 2022):

Outcome Odds ratio (95% CI) Trials Participants
All-cause mortality 1.02 (0.97–1.07) 9 107,772
Cardiovascular events 0.96 (0.90–1.04) 4 62,136
Cancer incidence 1.02 (0.98–1.08) 5 76,777

On that basis, the USPSTF concluded with moderate certainty that vitamin E has no net benefit and recommended against it for preventing cardiovascular disease or cancer (USPSTF, JAMA 2022). It gave the same D recommendation for beta-carotene, for which it found harms outweighed benefits.

Prostate cancer: conflicting results

The prostate cancer story is less settled than either side often suggests:

  • ATBC. In male smokers, 50 mg/day lowered prostate cancer incidence by 32% (NIH ODS). At 18 years of post-trial follow-up, prostate cancer mortality remained lower (RR 0.84; 95% CI 0.70–0.99), while post-trial overall mortality did not differ (RR 1.02; 0.98–1.05) (Virtamo et al., Int J Cancer 2014).
  • SELECT. This trial was designed partly on the ATBC finding. Instead of prevention, it found more prostate cancer with vitamin E alone (620 vs 529 cases). The vitamin E plus selenium arm was not significantly different from placebo (HR 1.05; 99% CI 0.89–1.22) (Klein et al., JAMA 2011).
  • Selenium status. In a SELECT case-cohort analysis, vitamin E raised total and high-grade prostate cancer in men with lower baseline toenail selenium (63%, P = .02; and 111%, P = .008), with no effect in men with higher status (Kristal et al., J Natl Cancer Inst 2014).
  • Regulators. After reviewing all of this in 2024, EFSA considered the evidence insufficient to conclude on a relationship between alpha-tocopherol intake and prostate cancer risk (EFSA 2024).

All-cause mortality

Meta-analyses disagree, mostly because they pool different trials. None shows a survival benefit.

Analysis Trials and people Result
Miller et al., Ann Intern Med 2005 19 trials; 135,967 people At 400 IU/day or more: 39 extra deaths per 10,000 (95% CI 3–74). Risk rose above 150 IU/day in dose-response analysis
Bjelakovic et al., Cochrane 2012 46 low-bias vitamin E trials, alone or with other antioxidants RR 1.03 (95% CI 1.00–1.05)
Abner et al., Curr Aging Sci 2011 57 trials of at least 1 year; 246,371 people RR 1.00 (95% CI 0.98–1.02); no dose relationship
Curtis et al., Cardiovasc Drugs Ther 2014 18 trials in apparently healthy people; 142,219 people RR 1.01 (95% CI 0.97–1.05); no association in subgroups by natural or synthetic form

Miller’s authors noted that their high-dose trials were often small and done in people with chronic disease, so the result may not apply to healthy adults. The Cochrane authors concluded that vitamin E seems to increase mortality, while the ODS calls the implications of these signals unclear. A fair reading is that any increase in mortality is small and disputed, and that a survival benefit has not been shown at any dose.

Antioxidant doses and training adaptations

Exercise produces reactive oxygen species, which may also act as signals that drive adaptation. This has led to trials asking whether high-dose antioxidants blunt training gains. All the trials below gave vitamin E together with vitamin C, so they cannot isolate the effect of vitamin E, and all are small.

Study Who Daily dose Training Result vs placebo
Paulsen et al., J Physiol 2014 (endurance) 54 young men and women Vitamin C 1,000 mg, vitamin E 235 mg 11 weeks, endurance VO2max rose 8% in both groups; mitochondrial markers COX4 and PGC-1α rose only on placebo
Ristow et al., PNAS 2009 39 young men Vitamin C 1,000 mg, vitamin E 400 IU 4 weeks Insulin sensitivity improved only without antioxidants
Yfanti et al., Am J Physiol 2011 21 young men Vitamin C 500 mg, vitamin E 400 IU 12 weeks, endurance Insulin-stimulated glucose uptake rose similarly (17.2% vs 18.9%); VO2max rose similarly
Paulsen et al., J Physiol 2014 (strength) 32 recreationally strength-trained adults Vitamin C 1,000 mg, vitamin E 235 mg 10 weeks, heavy resistance Muscle growth and acute protein synthesis unaffected; biceps curl strength gain hampered; hypertrophy signaling blunted
Bjørnsen et al., Scand J Med Sci Sports 2016 34 men aged 60–81 Vitamin C 500 mg, vitamin E 117.5 mg, before and after training 12 weeks, strength Lean mass +1.4% vs +3.9% on placebo (P = 0.04); 1RM gains similar
Martínez-Ferrán et al., Nutrition 2023 23 trained men Vitamins C and E 10 weeks, resistance with calorie surplus Upper-body fat-free mass rose only on placebo (small effect size); 1RM gains similar; visceral fat rose only on placebo
Liu et al., Medicine 2025 60 women aged 60–75 with sarcopenia Vitamin C 1,000 mg, vitamin E 335 mg 12 weeks, elastic band Greater gains on antioxidants: arm lean mass 0.96 vs 0.59 kg, handgrip 3.66 vs 1.16 kg

The results point in the same direction more often than not, but they are not uniform. High doses frequently dampened cellular signaling and sometimes reduced muscle or strength gains, yet performance outcomes such as VO2max were usually unchanged, and one trial in older women with sarcopenia found added benefit. We did not find evidence that high-dose vitamin E improves muscle growth or performance in healthy trained people.

The recovery claim is also weak. A Cochrane review of 50 trials and 1,089 participants, covering all antioxidants rather than vitamin E alone, found less muscle soreness on paper. On a 0–10 cm scale the differences (for example −0.41 cm at 48 hours) were well below the minimal important difference of 1.4 cm. The authors concluded that high-dose antioxidants do not produce a clinically relevant reduction in soreness (Ranchordas et al., Cochrane 2017).

Testosterone

One analysis measured androgens directly. In 200 matched men from the ATBC trial, those on 50 mg/day had slightly lower serum testosterone at follow-up (539 vs 573 ng/dL; P = 0.04) and lower androstenedione (145 vs 158 ng/dL; P = 0.04) (Hartman et al., Prostate 2001). This is one study in older smokers, and its clinical importance is unknown. We found no placebo-controlled trial showing that vitamin E raises testosterone.

Fatty liver disease (NAFLD, now MASLD and MASH)

Nonalcoholic steatohepatitis (NASH), now called metabolic dysfunction-associated steatohepatitis (MASH), is the inflammatory form of fatty liver disease. This is the best-supported therapeutic use of vitamin E, though results depend on the population and the endpoint.

Trial Who Dose Duration Main results
PIVENS, Sanyal et al., NEJM 2010 247 adults with NASH, no diabetes 800 IU/day (vs pioglitazone or placebo) 96 weeks Histologic improvement 43% vs 19% on placebo (P = 0.001); fibrosis not improved (P = 0.24)
TONIC, Lavine et al., JAMA 2011 173 children aged 8–17 with NAFLD 800 IU/day (vs metformin or placebo) 96 weeks Primary endpoint missed: sustained ALT reduction 26% vs 17% (P = .26). In those with NASH, resolution 58% vs 28% (P = .006)
Bril et al., Diabetes Care 2019 105 adults with type 2 diabetes and NASH 400 IU twice daily, alone or with pioglitazone 18 months Vitamin E alone missed the primary endpoint: 31% vs 19% (P = 0.26). NASH resolution 33% vs 12% (P = 0.04). Combination 54% vs 19% (P = 0.003). No fibrosis benefit
Song et al., Cell Rep Med 2025 124 Chinese adults with MASH, no diabetes 300 mg/day natural 96 weeks Histologic improvement 29.3% vs 14.1% (OR 2.5; 95% CI 1.0–7.1; P = 0.04). MASH resolution without fibrosis worsening 12.1% vs 17.2% (P = 0.43)
VEDS, Dasarathy et al., Hepatology 2026 200 adults with suspected MASH and ALT of 60 U/L or higher 200, 400 or 800 IU/day natural 24 weeks ALT −38%, −36%, −36% vs −12% on placebo (P ≤ 0.001 for all); liver fat and stiffness changes not significant

Fibrosis remains the weak point. PIVENS and Bril found no improvement. In Song, fibrosis improvement by at least one stage was not significantly different (25.9% vs 15.6%; P = 0.16), although the fibrosis score analysis favored vitamin E (win ratio 2.1; P = 0.04). The authors noted that dropout exceeded expectations during the COVID-19 pandemic.

Other evidence adds context:

  • Cochrane 2024. Pooling 16 trials and 1,066 participants at 298–1,000 IU/day, vitamin E likely reduced ALT slightly (mean difference −9.29; 95% CI −13.69 to −4.89; moderate certainty). Effects on mortality and serious adverse events were very uncertain (all-cause mortality RR 3.45; 95% CI 0.57–20.86; 3 trials), and there were no data on liver-related death or illness. The authors said it is unknown whether the enzyme reduction affects the course of disease (Wen et al., Cochrane 2024).
  • Long-term outcomes. In a retrospective study, 90 patients with NASH and bridging fibrosis or cirrhosis who took 800 IU/day for at least 2 years were matched to 90 who did not. Users had less death or transplant (adjusted HR 0.30; 95% CI 0.12–0.74) and less liver decompensation (adjusted sub-HR 0.52; 95% CI 0.28–0.96) (Vilar-Gomez et al., Hepatology 2020). This is observational and cannot prove cause.
  • Guidance. The AASLD’s 2023 guidance says vitamin E “can be considered in select individuals as it improves NASH in some patients without diabetes.” It adds that no study has shown a meaningful reduction in fibrosis, and that bleeding, hemorrhagic stroke and prostate cancer concerns should be discussed before long-term high-dose treatment (Rinella et al., Hepatology 2023).
  • Approved drugs. Vitamin E is not an FDA-approved MASH treatment. In 2024 the FDA approved resmetirom for noncirrhotic disease with moderate to advanced fibrosis (FDA 2024), and semaglutide later gained a similar indication under accelerated approval.

The doses matter for safety. At 0.67 mg per IU, the 800 IU/day used in PIVENS is about 536 mg/day: under the US limit but above Europe’s 300 mg/day. Lower doses are being studied for that reason, although the 200 IU/day result in VEDS is based on ALT over 24 weeks, not on biopsy.

We found no human trial testing vitamin E against liver injury from anabolic steroids. The data above come from metabolic fatty liver disease and should not be assumed to apply to drug-induced injury.

Other uses

  • Eye disease. In people at high risk of advanced age-related macular degeneration, the AREDS formula (vitamin E plus beta-carotene, vitamin C, zinc and copper) lowered the risk of advanced disease by 25% at 5 years. Two prevention trials of vitamin E, one of which also gave beta-carotene, showed no protection, and AREDS showed no effect on cataracts (NIH ODS).
  • Alzheimer’s disease. In a trial with 561 analyzed patients with mild to moderate disease, 2,000 IU/day slowed functional decline by 3.15 points on a 78-point scale over a mean 2.27 years (Dysken et al., JAMA 2014). A trial in mild cognitive impairment found no slowing of progression to Alzheimer’s, and most research does not support use for maintaining cognition in healthy or mildly impaired people (NIH ODS).

Side effects and risks

No adverse effects have been reported from large amounts of vitamin E in food. The concerns below involve supplements (NIH ODS).

Bleeding and hemorrhagic stroke

A meta-analysis of 9 trials and 118,765 people separated stroke by type (Schürks et al., BMJ 2010):

Stroke type Pooled RR (95% CI) Absolute effect
Total 0.98 (0.91–1.05) No net effect
Hemorrhagic 1.22 (1.00–1.48) 1 extra per 1,250 people
Ischemic 0.90 (0.82–0.99) 1 fewer per 476 people

The authors cautioned against widespread use because hemorrhagic strokes are generally more severe. Signals appeared at modest doses: 50 mg/day in ATBC, and 400 IU of synthetic vitamin E on alternate days in Physicians’ Health Study II, where most men were also taking aspirin (NIH ODS). The Women’s Health Study found no significant effect on ischemic or hemorrhagic stroke.

EFSA noted that the trials showing more hemorrhagic stroke included many people on secondary prevention or antiplatelet drugs. It therefore did not use them to set its limit, and it said such people should take vitamin E only under medical supervision (EFSA 2024).

Reduced clotting may have an upside. In the Women’s Health Study, venous thromboembolism (blood clots in the veins) was less common with vitamin E (213 vs 269 cases; relative hazard 0.79; 95% CI 0.66–0.94) (Glynn et al., Circulation 2007). This was a secondary endpoint.

Anticoagulants and vitamin K

Vitamin E can inhibit platelets and oppose vitamin K-dependent clotting factors, so large doses may raise bleeding risk with anticoagulants such as warfarin, especially when vitamin K intake is low. The ODS says the amount needed for a clinically significant effect is unknown but probably exceeds 400 IU/day. The direct data are limited and mixed:

  • Vitamin K status. In 70 adults not on anticoagulants, 1,000 IU/day of natural vitamin E for 12 weeks raised PIVKA-II, a marker of poor vitamin K status, from 1.7 to 11.9 ng/mL in one study and from 1.8 to 5.3 ng/mL in the other (both P under 0.001). The clinical meaning is unclear (Booth et al., Am J Clin Nutr 2004).
  • Warfarin trial. In a small double-blind trial of 21 people on long-term warfarin, vitamin E did not significantly change INR (Kim & White, Am J Cardiol 1996). This trial is too small to rule out an interaction.
  • Observational data. Among 566 patients with atrial fibrillation on warfarin, those who bled had higher cholesterol-adjusted serum vitamin E (5.27 vs 4.48 μmol/mmol cholesterol; P under 0.001), rising with bleeding severity. This reflects blood levels rather than supplement use. The authors called for study in people on newer anticoagulants (Pastori et al., J Am Heart Assoc 2013).

Vitamin K2 works in the opposite direction on warfarin, reducing its effect. Prescription omega-3 products carry their own bleeding signal at high doses.

Heart failure

In HOPE and HOPE-TOO, 400 IU/day of natural vitamin E raised heart failure (RR 1.13) and heart failure hospitalization (RR 1.21; 95% CI 1.00–1.47) (Lonn et al., JAMA 2005). The ODS calls this an unexpected finding not reported in other large studies.

Other interactions

The NIH ODS also lists:

  • Simvastatin plus niacin. An antioxidant mix of vitamin E, vitamin C, selenium and beta-carotene blunted the rise in HDL cholesterol with this drug combination.
  • Chemotherapy and radiotherapy. Oncologists generally advise against antioxidants during treatment because they might protect cancer cells, though a systematic review questioned this and more research is needed.

Vaping: vitamin E acetate

Swallowing vitamin E esters and inhaling them are very different exposures. During the US outbreak of vaping-associated lung injury (EVALI), vitamin E acetate was found in lung fluid from 48 of 51 patients and in none of the healthy comparison group. Most patients had used THC vaping products (Blount et al., NEJM 2020).

In the US, vitamin E is sold as a dietary supplement, and labels list it in mg against a Daily Value of 15 mg (NIH ODS). Neither vitamin E nor tocopherol is named on the WADA 2026 Prohibited List.

Key takeaways

  • Essential, but deficiency is rare. The adult US RDA is 15 mg/day, and overt deficiency mostly occurs with fat malabsorption or rare genetic disorders. Synthetic dl-alpha-tocopherol has about half the activity per mg of the natural form.
  • No prevention benefit. Large trials found no reduction in cardiovascular events, cancer or death, and the USPSTF recommends against vitamin E for preventing cardiovascular disease or cancer.
  • Harm signals exist. Hemorrhagic stroke rose 22% in pooled trials. SELECT found 17% more prostate cancer at 400 IU/day, although ATBC found less at 50 mg/day and EFSA calls the overall prostate evidence insufficient.
  • No training upside shown. Vitamin C and E combinations often blunted cellular adaptations and sometimes muscle or strength gains, and antioxidants did not meaningfully reduce soreness.
  • Liver disease is the real niche. Vitamin E improved histology in nondiabetic adults with steatohepatitis but has not clearly improved fibrosis, and long-term randomized outcome data are missing.
  • Bleeding is the key interaction. EFSA’s limit does not cover people on anticoagulant or antiplatelet drugs, and its 300 mg/day adult value is far below the US 1,000 mg/day.

Sources

  1. National Institutes of Health Office of Dietary Supplements. Vitamin E: fact sheet for health professionals. Updated October 19, 2026. NIH ODS.
  2. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, et al. Scientific opinion on the tolerable upper intake level for vitamin E. EFSA J. 2024;22(8):e8953. PubMed.
  3. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific Opinion on Dietary Reference Values for vitamin E as α-tocopherol. EFSA J. 2015;13(7):4149. PubMed.
  4. Burton GW, Traber MG, Acuff RV, et al. Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr. 1998;67(4):669–684. PubMed.
  5. Traber MG, Leonard SW, Bobe G, et al. α-Tocopherol disappearance rates from plasma depend on lipid concentrations: studies using deuterium-labeled collard greens in younger and older adults. Am J Clin Nutr. 2015;101(4):752–759. PubMed.
  6. Yap SP, Yuen KH, Wong JW. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J Pharm Pharmacol. 2001;53(1):67–71. PubMed.
  7. Zuo S, Wang G, Han Q, et al. The effects of tocotrienol supplementation on lipid profile: a meta-analysis of randomized controlled trials. Complement Ther Med. 2020;52:102450. PubMed.
  8. Pervez MA, Khan DA, Mirza SA, et al. Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized double-blind active-controlled trial. Complement Ther Med. 2022;70:102866. PubMed.
  9. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029–1035. PubMed.
  10. Virtamo J, Taylor PR, Kontto J, et al. Effects of α-tocopherol and β-carotene supplementation on cancer incidence and mortality: 18-year postintervention follow-up of the Alpha-tocopherol, Beta-carotene Cancer Prevention Study. Int J Cancer. 2014;135(1):178–185. PubMed.
  11. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338–1347. PubMed.
  12. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):56–65. PubMed.
  13. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300(18):2123–2133. PubMed.
  14. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301(1):52–62. PubMed.
  15. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–1556. PubMed.
  16. Kristal AR, Darke AK, Morris JS, et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):djt456. PubMed.
  17. O’Connor EA, Evans CV, Ivlev I, et al. Vitamin and mineral supplements for the primary prevention of cardiovascular disease and cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;327(23):2334–2347. PubMed.
  18. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Vitamin, mineral, and multivitamin supplementation to prevent cardiovascular disease and cancer: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(23):2326–2333. PubMed.
  19. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46. PubMed.
  20. Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;2012(3):CD007176. PubMed.
  21. Abner EL, Schmitt FA, Mendiondo MS, et al. Vitamin E and all-cause mortality: a meta-analysis. Curr Aging Sci. 2011;4(2):158–170. PubMed.
  22. Curtis AJ, Bullen M, Piccenna L, et al. Vitamin E supplementation and mortality in healthy people: a meta-analysis of randomised controlled trials. Cardiovasc Drugs Ther. 2014;28(6):563–573. PubMed.
  23. Paulsen G, Cumming KT, Holden G, et al. Vitamin C and E supplementation hampers cellular adaptation to endurance training in humans: a double-blind, randomised, controlled trial. J Physiol. 2014;592(8):1887–1901. PubMed.
  24. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A. 2009;106(21):8665–8670. PubMed.
  25. Yfanti C, Nielsen AR, Akerström T, et al. Effect of antioxidant supplementation on insulin sensitivity in response to endurance exercise training. Am J Physiol Endocrinol Metab. 2011;300(5):E761–E770. PubMed.
  26. Paulsen G, Hamarsland H, Cumming KT, et al. Vitamin C and E supplementation alters protein signalling after a strength training session, but not muscle growth during 10 weeks of training. J Physiol. 2014;592(24):5391–5408. PubMed.
  27. Bjørnsen T, Salvesen S, Berntsen S, et al. Vitamin C and E supplementation blunts increases in total lean body mass in elderly men after strength training. Scand J Med Sci Sports. 2016;26(7):755–763. PubMed.
  28. Martínez-Ferrán M, Berlanga LA, Barcelo-Guido O, et al. Antioxidant vitamin supplementation on muscle adaptations to resistance training: a double-blind, randomized controlled trial. Nutrition. 2023;105:111848. PubMed.
  29. Liu X, Chen B, Jin Y, et al. Effects of vitamins C and E supplementation combined with 12-week resistance training in older women with sarcopenia: a randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2025;104(34):e43976. PubMed.
  30. Ranchordas MK, Rogerson D, Soltani H, et al. Antioxidants for preventing and reducing muscle soreness after exercise. Cochrane Database Syst Rev. 2017;12(12):CD009789. PubMed.
  31. Hartman TJ, Dorgan JF, Woodson K, et al. Effects of long-term alpha-tocopherol supplementation on serum hormones in older men. Prostate. 2001;46(1):33–38. PubMed.
  32. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685. PubMed.
  33. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–1668. PubMed.
  34. Bril F, Biernacki DM, Kalavalapalli S, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481–1488. PubMed.
  35. Song Y, Ni W, Zheng M, et al. Vitamin E (300 mg) in the treatment of MASH: a multi-center, randomized, double-blind, placebo-controlled study. Cell Rep Med. 2025;6(2):101939. PubMed.
  36. Dasarathy S, Mitchell EP, Wilson LA, et al. Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: a multicenter, randomized, placebo-controlled trial. Hepatology. Published online 2026. doi:10.1097/HEP.0000000000001797. PubMed.
  37. Wen H, Deng H, Yang L, et al. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2024;10(10):CD015033. PubMed.
  38. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495–509. PubMed.
  39. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. PubMed.
  40. US Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. March 14, 2024. FDA.
  41. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33–44. PubMed.
  42. Schürks M, Glynn RJ, Rist PM, et al. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702. PubMed.
  43. Glynn RJ, Ridker PM, Goldhaber SZ, et al. Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women’s Health Study. Circulation. 2007;116(13):1497–1503. PubMed.
  44. Booth SL, Golly I, Sacheck JM, et al. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr. 2004;80(1):143–148. PubMed.
  45. Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol. 1996;77(7):545–546. PubMed.
  46. Pastori D, Carnevale R, Cangemi R, et al. Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. J Am Heart Assoc. 2013;2(6):e000364. PubMed.
  47. Blount BC, Karwowski MP, Shields PG, et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med. 2020;382(8):697–705. PubMed.
  48. World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List.